Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cedazuridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA known ✓ | P32320 | 11/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cedazuridine SCHEMBL170217 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL13828324 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL10070522 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL10069553 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL23227281 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL24807958 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL10070136 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL25286013 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL19965745 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL19965746 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743074-A1 | METHODS OF TREATING HEMATOLOGIC CANCER | Foghorn Therapeutics Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260124190-A1 | METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2026-05-07 | — | — | US | claimed |
| EP-4727596-A2 | ANTIBODY-DRUG CONJUGATES AND LINKERS AND METHODS OF USE THEREOF | Ohio State Innovation Foundation (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| EP-4704834-A1 | RESPONSE-BASED DOSING FOR TREATING CANCER WITH A HYPOMETHYLATING AGENT AND CEDAZURIDINE | Taiho Pharmaceutical Co., Ltd. (JP) | 2026-03-11 | — | — | EP | claimed |
| US-12514866-B2 | Method for treating cancer | NATIONAL TAIWAN UNIVERSITY (TW) | 2026-01-06 | — | — | US | claimed |
| US-20260000697-A1 | COMBINATION FORMULATION OF CEDAZURIDINE | OTSUKA PHARMA CO LTD (JP) | 2026-01-01 | — | — | US | claimed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| US-20250288687-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATES AND DNMT INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-09-18 | — | — | US | claimed |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2025-08-14 | — | — | US | claimed |
| US-11660310-B2 | Low dose combination CDA substrate drug/cedazuridine with extended administration | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-05-30 | — | — | US | claimed |
| WO-2023078464-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | 上海弼领生物技术有限公司 | 2023-05-11 | — | — | WO | claimed |
| US-20230089147-A1 | COMBINATION DECITABINE AND CEDAZURIDINE SOLID ORAL DOSAGE FORMS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-03-23 | — | — | US | claimed |
| CN-115381939-A | Pharmaceutical composition for treating Hodgkin lymphoma and application thereof | 深圳微芯生物科技股份有限公司 | 2022-11-25 | — | — | CN | claimed |
| WO-2022221304-A1 | CO-INHIBITION OF CD47/SIRPα BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER | GILEAD SCIENCES, INC. (US) | 2022-10-20 | — | — | WO | claimed |
| WO-2022204126-A1 | TREATMENT OF RNA VIRUS INFECTION WITH A CYTIDINE DEAMINASE INHIBITOR | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-09-29 | — | — | WO | claimed |
| US-20220288047-A1 | METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | US | claimed |
| WO-2022187303-A1 | A METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2022-09-09 | — | — | WO | claimed |
| WO-2022093930-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-05-05 | — | — | WO | claimed |
| US-20220110958-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-04-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288047-A1 | METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | MCL1, IL5, MALT1 | CDA 2213/4885PDE4D 3988/4885PDE3A 1818/4885 |
| US-20260000697-A1 | COMBINATION FORMULATION OF CEDAZURIDINE | DCTD, EZH2, DUT | CDA 4/4885PDE4D 136/4885PDE3A 228/4885 |
| US-20220110958-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | CDA, DNMT1, DUT | CDA 1/4885PDE4D 2182/4885PDE3A 2945/4885 |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SLC7A1, KARS1, LNPEP | CDA 1286/4885PDE4D 3249/4885PDE3A 2974/4885 |
| US-20250288687-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATES AND DNMT INHIBITORS | DNMT1, DNMT3B, DNMT3A | CDA 342/4885PDE4D 2399/4885PDE3A 2004/4885 |
| US-20260124190-A1 | METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | IRAK2, IRAK3, IRAK1 | CDA 2389/4885PDE4D 2068/4885PDE3A 2658/4885 |
| US-20230089147-A1 | COMBINATION DECITABINE AND CEDAZURIDINE SOLID ORAL DOSAGE FORMS | DNMT3A, DNMT1, CDA | CDA 3/4885PDE4D 464/4885PDE3A 613/4885 |
| US-11660310-B2 | Low dose combination CDA substrate drug/cedazuridine with extended administration | CDA, DNMT1, DUT | CDA 1/4885PDE4D 2182/4885PDE3A 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.